Increasing Capacity
Capacity
There is a critical need to empower clinical researchers in Low- and Middle-Income Countries (LMICs) to lead the research response to epidemic infections. We offer a portfolio of research capacity building initiatives to support emerging clinical researchers in exchanging knowledge, gaining confidence in their research and leadership skills, developing local and regional research agendas, and ultimately increasing the international footprint of their institution both within ISARIC and further afield.
Collaboration is at the core of everything we do and our research capacity strengthening programmes focus on reaching out to, and working with a number of regional and international initiatives. Learn more about past and ongoing opportunities.
Clinical Research During Outbreaks (CREDO)
The CREDO training provides trainees with a set of skills to lead the research response in an outbreak, and strengthens the national capacities of LMICs to generate clinical evidence during outbreaks and facilitate networking and the sharing of resources.
Fellowship Programme
Latest news
Delphi survey launched by the ISARIC Dengue Core Outcome Set team
20 July 2024: The Dengue Core Outcome Set (DEN-CORE) team has officially launched the first round of their Delphi survey, focusing on outcomes for hospitalised patients with dengue. Individuals involved with dengue in any way are invited to participate in the definition of the most critical dengue outcomes by emailing dencore@isaric.org with an expression of interest. The survey is available in 11 languages: English, Bahasa, Hindi, Malay, Nepali, Portuguese, Spanish, Sinhala, Tagalog, Thai,
ISARIC’s response to H5N1 outbreak in the US: Case Report Form
18 June 2024: As part of ISARIC’s H5 readiness due to the increasing concern of H5N1 circulation in several mammals in the USA and the risk of transmission to dairy farm workers, ISARIC is releasing our CRF through all our networks and partners. We are working on aligning data variables with the World Health Organisation (WHO). This aligns with our commitment to strengthening evidence generation for emerging outbreaks. In the context of recent H5N1 infections in humans and increasing ...
Researchers successfully enrol over 220 cases for landmark plague trial
The first randomised controlled trial powered to evaluate the efficacy and safety of treatments for bubonic plague has enrolled over 220 cases of confirmed or probable bubonic plague in Madagascar, marking a critical milestone in plague treatment research. Plague has afflicted humanity for millennia, and is still a high-risk pathogen today. However, current treatments are based on weak evidence, as no conclusive clinical trial has ever been conducted. Until today. The IMASOY trial in ...